Uttam Prasad Panigrahy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Uttam Prasad Panigrahy has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Sathvik Belagodu Sridhar
College of Pharmacy, Dubai Medical University, Dubai P.O. Box 20170, United Arab Emirates
6 shared publications - Sumel Ashique
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India
6 shared publications - Anas Islam
Faculty of Pharmacy, Integral University, Lucknow, India
5 shared publications - Joy Das
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India
5 shared publications A. Sunil Kumar Reddy
4 shared publications- Shubhrajit Mantry
Department of Pharmacy, Sarala Birla University Birla Knowledge City, Ranchi, India
4 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Horizon E-Publishing Group in Plant Science Today
Exploring nature’s potential: A traditional and phytopharmacological review of Amaranthaceae family targeting JAK–STAT signalling pathway
The Amaranthaceae family, encompassing more than 175 genera and over 2000 species, represents one of the most diverse groups of angiosperms with profound ethnomedicinal, nutritional, pharmacological and ecological significance worldwide. Medicinally important species, including Amaranthus viridis L., Achyranthes bidentata Blume, Alternanthera sessilis (L.) DC. and Celosia argentea L., have been extensively utilised in Ayurveda, Siddha, traditional Chinese medicine (TCM) and numerous indigenous healthcare systems for the management of inflammatory disorders, diabetes mellitus, gastrointestinal diseases, reproductive ailments and wound healing. This critical review comprehensively elucidates the ethnobotanical relevance, phytochemical diversity, nutritional attributes and pharmacological potential of Amaranthaceae species, with particular emphasis on their modulation of the Janus kinase–signal transducer and activator of transcription (JAK–STAT) signalling pathway, a pivotal regulator of inflammation, immunity, cellular proliferation and apoptosis. Phytochemical investigations have revealed an extensive repertoire of bioactive metabolites, including flavonoids, alkaloids, saponins, terpenoids, phenolic acids and betalains, which collectively exhibit potent antioxidant, anti-inflammatory, antidiabetic, hepatoprotective, antimicrobial and immunomodulatory activities. Emerging experimental evidence suggests that several Amaranthaceae-derived phytoconstituents effectively regulate aberrant JAK–STAT signalling, thereby highlighting their potential as promising natural alternatives or complementary adjuncts to synthetic JAK inhibitors for the management of chronic inflammatory and immune-mediated disorders. Beyond their therapeutic applications, numerous species serve as nutrient-dense leafy vegetables and pseudocereals enriched with high-quality proteins, essential amino acids, dietary fibre, vitamins and minerals, contributing substantially to global food and nutritional security. Nevertheless, significant challenges persist regarding phytochemical standardisation, optimisation of bioavailability, comprehensive toxicological assessment, pharmacokinetic characterisation and rigorous clinical validation. Future multidisciplinary investigations integrating advanced phytochemical profiling, molecular pharmacology, systems biology, nanotechnology and well-designed clinical trials are indispensable to accelerate the translational development of Amaranthaceae-derived nutraceuticals and phytopharmaceuticals for inflammatory and immunological diseases.
- 18 November 2026
- Published by Horizon E-Publishing Group in Plant Science Today
Open AccessExploring nature’s potential: A traditional and phytopharmacological review of Amaranthaceae family targeting JAK–STAT signalling pathway
The Amaranthaceae family, encompassing more than 175 genera and over 2000 species, represents one of the most diverse groups of angiosperms with profound ethnomedicinal, nutritional, pharmacological and ecological significance worldwide. Medicinally important species, including Amaranthus viridis L., Achyranthes bidentata Blume, Alternanthera sessilis (L.) DC. and Celosia argentea L., have been extensively utilised in Ayurveda, Siddha, traditional Chinese medicine (TCM) and numerous indigenous healthcare systems for the management of inflammatory disorders, diabetes mellitus, gastrointestinal diseases, reproductive ailments and wound healing. This critical review comprehensively elucidates the ethnobotanical relevance, phytochemical diversity, nutritional attributes and pharmacological potential of Amaranthaceae species, with particular emphasis on their modulation of the Janus kinase–signal transducer and activator of transcription (JAK–STAT) signalling pathway, a pivotal regulator of inflammation, immunity, cellular proliferation and apoptosis. Phytochemical investigations have revealed an extensive repertoire of bioactive metabolites, including flavonoids, alkaloids, saponins, terpenoids, phenolic acids and betalains, which collectively exhibit potent antioxidant, anti-inflammatory, antidiabetic, hepatoprotective, antimicrobial and immunomodulatory activities. Emerging experimental evidence suggests that several Amaranthaceae-derived phytoconstituents effectively regulate aberrant JAK–STAT signalling, thereby highlighting their potential as promising natural alternatives or complementary adjuncts to synthetic JAK inhibitors for the management of chronic inflammatory and immune-mediated disorders. Beyond their therapeutic applications, numerous species serve as nutrient-dense leafy vegetables and pseudocereals enriched with high-quality proteins, essential amino acids, dietary fibre, vitamins and minerals, contributing substantially to global food and nutritional security. Nevertheless, significant challenges persist regarding phytochemical standardisation, optimisation of bioavailability, comprehensive toxicological assessment, pharmacokinetic characterisation and rigorous clinical validation. Future multidisciplinary investigations integrating advanced phytochemical profiling, molecular pharmacology, systems biology, nanotechnology and well-designed clinical trials are indispensable to accelerate the translational development of Amaranthaceae-derived nutraceuticals and phytopharmaceuticals for inflammatory and immunological diseases.
- 21 October 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 64 (8) , e70718
Modulating Microglial Activation Through GLP‐1 Pathways: A New Frontier in Neuroinflammation Research
Microglia are the immune cells resident in the central nervous system (CNS) and are involved in CNS homeostasis and in responses to injury and disease. Microglia, upon activation, become pro‐inflammatory (M1) or anti‐inflammatory (M2), with M1 being neurotoxic and M2 participating in tissue repair. The activation of microglia in neuroinflammation and pain hypersensitivity is important in the neurodegenerative disorders such as Parkinson's (PD) and Alzheimer's disease ( AD ). Recent investigations have identified GLP‐1 receptor agonists (GLP‐1 RAs) as potent pharmacological agents that can regulate the activity of the microglia. GLP‐1RA attaches to the GLP‐1 receptor found on the microglia to cause a phenotypic shift to the anti‐inflammatory M2 form, which, in turn, reduces neuroinflammation and increases neuronal protection. Experimental evidence shows that GLP‐1 RAs are effective at reducing hypersensitivity to pain, improving cognitive performance, and attenuating inflammatory effects in preclinical models of AD , PD, and multiple sclerosis (MS). All these facts suggest that GLP‐1 RAs are a significant treatment option in chronic pain and neurodegenerative disease management, as they can change microglial polarization and suppress neuroinflammation.
- 21 October 2026
- Published by Wiley in European Journal of Neuroscience
- Vol. 64 (8) , e70718
Modulating Microglial Activation Through GLP‐1 Pathways: A New Frontier in Neuroinflammation Research
Microglia are the immune cells resident in the central nervous system (CNS) and are involved in CNS homeostasis and in responses to injury and disease. Microglia, upon activation, become pro‐inflammatory (M1) or anti‐inflammatory (M2), with M1 being neurotoxic and M2 participating in tissue repair. The activation of microglia in neuroinflammation and pain hypersensitivity is important in the neurodegenerative disorders such as Parkinson's (PD) and Alzheimer's disease ( AD ). Recent investigations have identified GLP‐1 receptor agonists (GLP‐1 RAs) as potent pharmacological agents that can regulate the activity of the microglia. GLP‐1RA attaches to the GLP‐1 receptor found on the microglia to cause a phenotypic shift to the anti‐inflammatory M2 form, which, in turn, reduces neuroinflammation and increases neuronal protection. Experimental evidence shows that GLP‐1 RAs are effective at reducing hypersensitivity to pain, improving cognitive performance, and attenuating inflammatory effects in preclinical models of AD , PD, and multiple sclerosis (MS). All these facts suggest that GLP‐1 RAs are a significant treatment option in chronic pain and neurodegenerative disease management, as they can change microglial polarization and suppress neuroinflammation.
- 1 October 2026
- Published by Springer Nature in Toxicology and Environmental Health Sciences
- p. 1-19
Microplastics and gut dysbiosis: links to cancer inflammation
- 1 October 2026
- Published by Springer Nature in Toxicology and Environmental Health Sciences
- p. 1-19
Microplastics and gut dysbiosis: links to cancer inflammation
- 16 September 2026
- Published by Bentham Science Publishers Ltd. in Drug Metabolism and Bioanalysis
- Vol. 19, 1-12
Comprehensive Review on AQbD-Enabled Latest Advancements of Bioanalysis Using Hyphenated Techniques in Drug Product Development
Introduction: Bioanalysis is essential in current drug discovery and development research for the healthcare industry. Bioanalysis involves the assessment of analytes, such as medicines, metabolites, and biomarkers, in biological specimens. Methods: This method includes several stages, from sample collection to analysis and subsequent data reporting. The first phase is to gather samples from clinical or preclinical trials, which are then sent to the laboratory for faster analysis. The second step entails sample clean-up, or sample preparation, which is deemed an essential aspect of bioanalysis. Results: Liquid Chromatography-Tandem Mass Spectrometry (LC–MS/MS) is the most favored technique for separation and detection in bioanalytical laboratories. This stems from the enhanced selectivity and sensitivity of other vital techniques, such as LC-NMR, GC-MS, GC-IR, CE-MS, and GC-NMR, which enable precise and rapid analysis of complex sample mixtures, offering improved reproducibility and greater automation. Discussion: Moreover, comprehending the analyte's chemical structure and characteristics is crucial before initiating bioanalytical procedures. This review provides a thorough investigation into the design and validation of bioanalytical techniques utilizing the AQbD framework, in accordance with ICH rules that delineate GLP and controlled bioanalysis. Conclusion: This review also provides a comprehensive overview of the above-reported hyphenated techniques, employing Statistical Quality Control (SQC) monitoring and regulatory compliance using an advanced AQbD approach, highlighting their current status and future directions.
- 16 September 2026
- Published by Bentham Science Publishers Ltd. in Drug Metabolism and Bioanalysis
- Vol. 19, 1-12
Comprehensive Review on AQbD-Enabled Latest Advancements of Bioanalysis Using Hyphenated Techniques in Drug Product Development
Introduction: Bioanalysis is essential in current drug discovery and development research for the healthcare industry. Bioanalysis involves the assessment of analytes, such as medicines, metabolites, and biomarkers, in biological specimens. Methods: This method includes several stages, from sample collection to analysis and subsequent data reporting. The first phase is to gather samples from clinical or preclinical trials, which are then sent to the laboratory for faster analysis. The second step entails sample clean-up, or sample preparation, which is deemed an essential aspect of bioanalysis. Results: Liquid Chromatography-Tandem Mass Spectrometry (LC–MS/MS) is the most favored technique for separation and detection in bioanalytical laboratories. This stems from the enhanced selectivity and sensitivity of other vital techniques, such as LC-NMR, GC-MS, GC-IR, CE-MS, and GC-NMR, which enable precise and rapid analysis of complex sample mixtures, offering improved reproducibility and greater automation. Discussion: Moreover, comprehending the analyte's chemical structure and characteristics is crucial before initiating bioanalytical procedures. This review provides a thorough investigation into the design and validation of bioanalytical techniques utilizing the AQbD framework, in accordance with ICH rules that delineate GLP and controlled bioanalysis. Conclusion: This review also provides a comprehensive overview of the above-reported hyphenated techniques, employing Statistical Quality Control (SQC) monitoring and regulatory compliance using an advanced AQbD approach, highlighting their current status and future directions.
- 8 September 2026
- Published by Springer Nature in Genome Instability & Disease
- Vol. 7 (4) , 20
Circular RNAs at the crossroads of oxidative stress: novel targets for precision therapeutics
- 8 September 2026
- Published by Springer Nature in Genome Instability & Disease
- Vol. 7 (4) , 20
Circular RNAs at the crossroads of oxidative stress: novel targets for precision therapeutics
- 31 August 2026
- Published by Springer Nature in VirusDisease
- Vol. 37 (3) , 253-270
An updated review of monkeypox virus infection's global prevalence and health risks with supporting treatment and diagnosis
- 31 August 2026
- Published by Springer Nature in VirusDisease
- Vol. 37 (3) , 253-270
An updated review of monkeypox virus infection's global prevalence and health risks with supporting treatment and diagnosis
- 20 April 2026
- Published by Wiley in Biomedical Chromatography
- Vol. 40 (6) , e70445
Multidimensional and Hybrid Separation Strategies for Body Fluids and Tissues: Comparative Performance and Translational Considerations
Analytical technologies for body fluids and tissues have advanced substantially over the past decade, particularly in chromatographic, electrophoretic and ion‐mobility–based separation strategies designed to address matrix complexity and structural isomerism. Improvements in stationary‐phase chemistry, multidimensional liquid chromatography, capillary electrophoresis and mobility‐integrated mass spectrometry have enhanced peak capacity, structural discrimination, remains the selection and validation of separation strategies capable of minimizing coelution, ion suppression and quantitative variability in heterogeneous matricesremains the selection and validation of separation strategies capable of minimizing coelution, ion suppression and quantitative variability in heterogeneous matrices. This review examines recent progress in multidimensional chromatography, mobility‐resolved workflows, miniaturized separation systems and hybrid imaging–separation platforms, with emphasis on comparative performance, practical implementation constraints and translational reproducibility. Applications across plasma, serum, urine, saliva, cerebrospinal fluid (CSF), tissues and spatially resolved analyses are discussed in the context of analyte chemistry and matrix‐dependent method selection. Future progress will depend on standardized multidimensional workflows, validated performance metrics, harmonized reporting frameworks and data‐driven optimization strategies that support robust clinical translation. By focusing on separation‐centred decision‐making and quality assurance, this review provides guidance for analytical scientists seeking reliable molecular characterization of complex human biospecimens.
- 20 April 2026
- Published by Wiley in Biomedical Chromatography
- Vol. 40 (6) , e70445
Multidimensional and Hybrid Separation Strategies for Body Fluids and Tissues: Comparative Performance and Translational Considerations
Analytical technologies for body fluids and tissues have advanced substantially over the past decade, particularly in chromatographic, electrophoretic and ion‐mobility–based separation strategies designed to address matrix complexity and structural isomerism. Improvements in stationary‐phase chemistry, multidimensional liquid chromatography, capillary electrophoresis and mobility‐integrated mass spectrometry have enhanced peak capacity, structural discrimination, remains the selection and validation of separation strategies capable of minimizing coelution, ion suppression and quantitative variability in heterogeneous matricesremains the selection and validation of separation strategies capable of minimizing coelution, ion suppression and quantitative variability in heterogeneous matrices. This review examines recent progress in multidimensional chromatography, mobility‐resolved workflows, miniaturized separation systems and hybrid imaging–separation platforms, with emphasis on comparative performance, practical implementation constraints and translational reproducibility. Applications across plasma, serum, urine, saliva, cerebrospinal fluid (CSF), tissues and spatially resolved analyses are discussed in the context of analyte chemistry and matrix‐dependent method selection. Future progress will depend on standardized multidimensional workflows, validated performance metrics, harmonized reporting frameworks and data‐driven optimization strategies that support robust clinical translation. By focusing on separation‐centred decision‐making and quality assurance, this review provides guidance for analytical scientists seeking reliable molecular characterization of complex human biospecimens.
- 4 March 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5053-5066
Current advances in 7-hydroxycoumarin derivatives as potential therapeutic agents for Alzheimer’s disease
Alzheimer’s disease (AD), a multifactorial neurodegenerative disorder, remains a major cause of cognitive decline in the aging population. Current pharmacological interventions provide only symptomatic relief, highlighting the urgent need for novel therapeutic strategies capable of modifying disease progression. Coumarins, particularly 7-hydroxycoumarin and its synthetic derivatives, have attracted considerable interest due to their broad pharmacological potential, including cholinesterase inhibition, monoamine oxidase (MAO) inhibition, antioxidant, anti-amyloidogenic and metal-chelating activities. This review presents a comprehensive analysis of synthetic 7-hydroxycoumarin derivatives reported over the past 15 years as potential anti-Alzheimer agents, classifying them according to their actions on key pathological hallmarks of AD, such as acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), MAO-B, β-amyloid (Aβ) aggregation, oxidative stress and neuroinflammation. Structure–activity relationship (SAR) analysis reveals that substitutions at the 7-, 3- and 4-positions of the coumarin scaffold critically influence pharmacological potency and selectivity, with aromatic and alkyl amine substitutions generally enhancing enzyme inhibition and neuroprotective effects. Several derivatives exhibited sub-micromolar to nanomolar inhibitory activity against AChE and MAO-B, along with antioxidant and anti-Aβ aggregation properties, supporting their multifunctional behaviour. Overall, this review highlights the therapeutic promise of 7-hydroxycoumarin derivatives as multitarget-directed ligands (MTDLs) and provides valuable insights for the rational design of new lead compounds for Alzheimer’s disease. Graphical abstract
- 4 March 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5053-5066
Current advances in 7-hydroxycoumarin derivatives as potential therapeutic agents for Alzheimer’s disease
Alzheimer’s disease (AD), a multifactorial neurodegenerative disorder, remains a major cause of cognitive decline in the aging population. Current pharmacological interventions provide only symptomatic relief, highlighting the urgent need for novel therapeutic strategies capable of modifying disease progression. Coumarins, particularly 7-hydroxycoumarin and its synthetic derivatives, have attracted considerable interest due to their broad pharmacological potential, including cholinesterase inhibition, monoamine oxidase (MAO) inhibition, antioxidant, anti-amyloidogenic and metal-chelating activities. This review presents a comprehensive analysis of synthetic 7-hydroxycoumarin derivatives reported over the past 15 years as potential anti-Alzheimer agents, classifying them according to their actions on key pathological hallmarks of AD, such as acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), MAO-B, β-amyloid (Aβ) aggregation, oxidative stress and neuroinflammation. Structure–activity relationship (SAR) analysis reveals that substitutions at the 7-, 3- and 4-positions of the coumarin scaffold critically influence pharmacological potency and selectivity, with aromatic and alkyl amine substitutions generally enhancing enzyme inhibition and neuroprotective effects. Several derivatives exhibited sub-micromolar to nanomolar inhibitory activity against AChE and MAO-B, along with antioxidant and anti-Aβ aggregation properties, supporting their multifunctional behaviour. Overall, this review highlights the therapeutic promise of 7-hydroxycoumarin derivatives as multitarget-directed ligands (MTDLs) and provides valuable insights for the rational design of new lead compounds for Alzheimer’s disease. Graphical abstract
- 2 February 2026
- Published by Springer Nature in Archives of Microbiology
- Vol. 208 (4) , 163
Modulating drug response through the gut microbiome: pathways to precision therapy
The mutual association formed between the gut flora and the biological host is pivotal, mainly for drug action. Various examination has spotlighted the potential consequences of the gut microbiome on drug efficacy, revealing its role in controlling metabolism in the body. Furthermore, reciprocal engagement has been examined to investigate how pharmaceutical agents influence the composition of the gut microbiome. This paper emphasizes the intricate relationship between pharmacology and environmental microbiology, directing the extensive significance of pharmaceutical agents on health by controlling the gut microbial consortium. One main highlight of this review is to determine the differences observed in populace as a result of drugs, which is a crucial component in boosting personalized treatment approaches and intensifying therapeutic findings. Apart from their function in drug metabolization, the gut microbiota is disclosed as a source of metabolic products that can alter drug action. These microbially-derived metabolites could notably effect drug results and changes the body’s physical mechanisms. The investigation suggests utilizing metabolomics to disclose the complications of gut microbiota–drug interactions. Several latest analytical strategies provide an effective tool for deciphering the complicated association among microbiome-generated fragments and pharmaceutical products, providing detailed understanding into this interesting connection. Graphical abstract
- 2 February 2026
- Published by Springer Nature in Archives of Microbiology
- Vol. 208 (4) , 163
Modulating drug response through the gut microbiome: pathways to precision therapy
The mutual association formed between the gut flora and the biological host is pivotal, mainly for drug action. Various examination has spotlighted the potential consequences of the gut microbiome on drug efficacy, revealing its role in controlling metabolism in the body. Furthermore, reciprocal engagement has been examined to investigate how pharmaceutical agents influence the composition of the gut microbiome. This paper emphasizes the intricate relationship between pharmacology and environmental microbiology, directing the extensive significance of pharmaceutical agents on health by controlling the gut microbial consortium. One main highlight of this review is to determine the differences observed in populace as a result of drugs, which is a crucial component in boosting personalized treatment approaches and intensifying therapeutic findings. Apart from their function in drug metabolization, the gut microbiota is disclosed as a source of metabolic products that can alter drug action. These microbially-derived metabolites could notably effect drug results and changes the body’s physical mechanisms. The investigation suggests utilizing metabolomics to disclose the complications of gut microbiota–drug interactions. Several latest analytical strategies provide an effective tool for deciphering the complicated association among microbiome-generated fragments and pharmaceutical products, providing detailed understanding into this interesting connection. Graphical abstract
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 513
Decoding Neuroinflammatory Pathways: The Role of the CXCL12-CXCR4/CXCR7 Axis in ALS-Related Cognitive Impairment
Cognitive impairment (CI) and accelerating neuronal deterioration are hallmarks of amyotrophic lateral sclerosis (ALS). Under these circumstances a crucial molecular mechanism in the pathophysiology of CI has been identified: the CXC chemokine receptor type 7 (CXCR7)/CXC chemokine receptor type 4 (CXCR4)/Cysteine-X-cysteine chemokine ligand 12 (CXCL12) region. Research on ALS shows that the CXCR7/CXCR4/CXCL12 complex plays a role in the degeneration of motor neurons and the resulting cognitive decline. JAK/STAT, PI3K/AKT, MAPK, and other signaling pathways are among the ways the axis controls neuronal inflammation, synaptic remodeling, and neuronal maintenance in each of these scenarios. The CXC motif chemokine ligand 12 (CXCL12) and CXC chemokine receptor type 4 (CXCR4) axis is crucial for the start of the inflammatory mechanism because of their function in mediating the chemotaxis of inflammatory cells. By preventing the migration of inflammatory cells via CXCL12 in the inflammatory area, the response to inflammation can be prevented or reduced. Consequently, the development of CXCR4 antagonists has emerged as a cutting-edge strategy for inflammation treatment. Recent research suggests that managing this relationship could reduce cognitive deficits and offer neuroprotective benefits. According to the current review, the CXCL12/CXCR4/CXCR7 pathway may be a promising target for treating cognitive dysfunction in neurodegenerative disorder. It also emphasizes the need for additional research to completely comprehend its function and identify efficient treatments which may result in improved clinical treatment modalities for these debilitating illnesses. Graphical Abstract
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 513
Decoding Neuroinflammatory Pathways: The Role of the CXCL12-CXCR4/CXCR7 Axis in ALS-Related Cognitive Impairment
Cognitive impairment (CI) and accelerating neuronal deterioration are hallmarks of amyotrophic lateral sclerosis (ALS). Under these circumstances a crucial molecular mechanism in the pathophysiology of CI has been identified: the CXC chemokine receptor type 7 (CXCR7)/CXC chemokine receptor type 4 (CXCR4)/Cysteine-X-cysteine chemokine ligand 12 (CXCL12) region. Research on ALS shows that the CXCR7/CXCR4/CXCL12 complex plays a role in the degeneration of motor neurons and the resulting cognitive decline. JAK/STAT, PI3K/AKT, MAPK, and other signaling pathways are among the ways the axis controls neuronal inflammation, synaptic remodeling, and neuronal maintenance in each of these scenarios. The CXC motif chemokine ligand 12 (CXCL12) and CXC chemokine receptor type 4 (CXCR4) axis is crucial for the start of the inflammatory mechanism because of their function in mediating the chemotaxis of inflammatory cells. By preventing the migration of inflammatory cells via CXCL12 in the inflammatory area, the response to inflammation can be prevented or reduced. Consequently, the development of CXCR4 antagonists has emerged as a cutting-edge strategy for inflammation treatment. Recent research suggests that managing this relationship could reduce cognitive deficits and offer neuroprotective benefits. According to the current review, the CXCL12/CXCR4/CXCR7 pathway may be a promising target for treating cognitive dysfunction in neurodegenerative disorder. It also emphasizes the need for additional research to completely comprehend its function and identify efficient treatments which may result in improved clinical treatment modalities for these debilitating illnesses. Graphical Abstract